Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Heron Therapeutics (HRTX) Cash from Financing Activities: 2010-2025

Historic Cash from Financing Activities for Heron Therapeutics (HRTX) over the last 11 years, with Sep 2025 value amounting to $13.4 million.

  • Heron Therapeutics' Cash from Financing Activities rose 95350.00% to $13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $14.6 million, marking a year-over-year increase of 1943.44%. This contributed to the annual value of $940,000 for FY2024, which is 98.26% down from last year.
  • Latest data reveals that Heron Therapeutics reported Cash from Financing Activities of $13.4 million as of Q3 2025, which was up 1,611.01% from $781,000 recorded in Q2 2025.
  • Heron Therapeutics' Cash from Financing Activities' 5-year high stood at $154.7 million during Q2 2021, with a 5-year trough of -$637,000 in Q1 2022.
  • Moreover, its 3-year median value for Cash from Financing Activities was $319,000 (2023), whereas its average is $6.3 million.
  • Within the past 5 years, the most significant YoY rise in Heron Therapeutics' Cash from Financing Activities was 105,652.11% (2022), while the steepest drop was 172.14% (2022).
  • Over the past 5 years, Heron Therapeutics' Cash from Financing Activities (Quarterly) stood at $487,000 in 2021, then dropped by 9.86% to $439,000 in 2022, then slumped by 54.67% to $199,000 in 2023, then surged by 112.56% to $423,000 in 2024, then surged by 95,350.00% to $13.4 million in 2025.
  • Its Cash from Financing Activities stands at $13.4 million for Q3 2025, versus $781,000 for Q2 2025 and $64,000 for Q1 2025.